Journal Watch · Journal of Allergy and Clinical Immunology · 2026

Human retinoic acid-inducible gene I (RIG-I) deficiency associated with susceptibility to classic Kaposi sarcoma.

Additional patients will clarify the virus susceptibility spectrum.

Roussel L, Bernier S, Langelier M et al.Journal of Allergy and Clinical Immunology3 min readPharma relevance 65/100

DOI: 10.1016/j.jaci.2026.02.027PMID: 41780571Study type: in-vitro / cell study

TL;DR

Additional patients will clarify the virus susceptibility spectrum.

Key findings

  • The findings extend RIG-I's antiviral relevance beyond RNA viruses.
  • Additional patients will clarify the virus susceptibility spectrum.

What they did

RIG-I-dependent antiviral signaling was evaluated through functional studies using fluorescent KSHV in patient-derived lymphoblastoid cell lines and isogenic fibroblast and endothelial models. Aberrant cellular responses during KSHV infection, latency, and reactivation in the context of RIG-I deficiency were assessed through transcriptomic, proteomic, and live-cell imaging analyses.<h4>Results</h4>A homozygous nonsense DDX58 mutation (p.Q393∗) was identified in a patient with classic KS, abolishing RIG-I expression and specifically impairing responses to RIG-I agonists. Loss of RIG-I compromised type I interferon responses to both primary KSHV infection and virus reactivation, with skewing to a persistent latent viral program and dysregulating cellular pro-oncogenic pathways.<h4>Conclusion</h4>This study links RIG-I deficiency to classic KS and supports its role as a candidate inborn error of innate immunity shaping KSHV pathogenesis.

Full abstract (original)

Background: <h4>Background</h4>Kaposi sarcoma (KS), driven by the DNA virus KS-associated herpesvirus (KSHV), arises in the context of T-cell immunosuppression (eg, human immunodeficiency virus infection, transplantation) or sporadically in ostensibly immunocompetent older adults (endemic or classic KS). The mechanisms underlying KS development without exogenous immunosuppression remain unclear. Retinoic acid-inducible gene I (RIG-I), encoded by DDX58, is a canonical cytosolic sensor of RNA viruses, but its role in human immunity to DNA viruses is not well understood.<h4>Objective</h4>We report a patient with RIG-I deficiency and KS and define associated antiviral and host response defects.<h4>Methods</h4>Whole-exome sequencing was performed to identify the genetic basis of the immunodeficiency.

What they did: RIG-I-dependent antiviral signaling was evaluated through functional studies using fluorescent KSHV in patient-derived lymphoblastoid cell lines and isogenic fibroblast and endothelial models. Aberrant cellular responses during KSHV infection, latency, and reactivation in the context of RIG-I deficiency were assessed through transcriptomic, proteomic, and live-cell imaging analyses.<h4>Results</h4>A homozygous nonsense DDX58 mutation (p.Q393∗) was identified in a patient with classic KS, abolishing RIG-I expression and specifically impairing responses to RIG-I agonists. Loss of RIG-I compromised type I interferon responses to both primary KSHV infection and virus reactivation, with skewing to a persistent latent viral program and dysregulating cellular pro-oncogenic pathways.<h4>Conclusion</h4>This study links RIG-I deficiency to classic KS and supports its role as a candidate inborn error of innate immunity shaping KSHV pathogenesis.

Results & conclusions: The findings extend RIG-I's antiviral relevance beyond RNA viruses. Additional patients will clarify the virus susceptibility spectrum.

Abstract © the authors / Journal of Allergy and Clinical Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jaci.2026.02.027 · PubMed 41780571.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Allergy and Clinical Immunology study find?

Additional patients will clarify the virus susceptibility spectrum.

What type of study is this?

It is a in-vitro / cell study, published in Journal of Allergy and Clinical Immunology in 2026. RIG-I-dependent antiviral signaling was evaluated through functional studies using fluorescent KSHV in patient-derived lymphoblastoid cell lines and isogenic fibroblast and endothelial models.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jaci.2026.02.027. PubMed ID: 41780571. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Roussel L, Bernier S, Langelier M et al.. Human retinoic acid-inducible gene I (RIG-I) deficiency associated with susceptibility to classic Kaposi sarcoma.. Journal of Allergy and Clinical Immunology (2026). DOI: 10.1016/j.jaci.2026.02.027.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/human-retinoic-acid-inducible-gene-i-rig-i-deficiency-associated-with-su-602027/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides